Advesya

Just a reminder that our CEO Ksenija Pavletic and our CSO Richard C. A. Sainson will be attending the upcoming ESMO conference starting next week on September 13th Our colleagues will be there to discuss our innovative approach to targeting IL1RAP using our cell therapy, #CCTx001, and our ADCs, #ADV101, which are currently being developed for the treatment of AML and solid tumors. If you're attending, they’d love to connect—reach out and learn more! 🌍🤝 #ESMO2024 #ADCs #SolidTumors #Oncology #Innovation #Collaboration #CellTherapy #Networking #AML #ADV101 #CCTx001

🌍🔬 Today is World Leukemia Day—a day to raise awareness and show support for everyone affected by leukemia. At Advesya, we are deeply committed to advancing the fight against leukemia. Our team is dedicated to developing innovative solutions and provide new life-saving treatments to patients across the globe. Let’s come together today to raise awareness and continue pushing forward in the mission to find a cure. 🎗️ 💛 🩸 #WorldLeukemiaDay #FightLeukemia #InnovateForLife #ResearchForACure #CCTx001 #ADV101 #AML

🔬 Really interesting to read about this new study on targeting IL-1RAP in AML! IL-1RAP is highly expressed on AML blasts and leukemic stem cells but not on healthy Hematopoietic stem cells, making it an ideal target for selective cancer therapy. This research introduces a T-cell engager that specifically targets IL-1RAP on AML cells and LSCs, showing great promise in eliminating the disease with minimal impact on healthy cells. Targeting IL-1RAP could revolutionize AML treatment, especially for patients with relapsed or refractory disease, by addressing the root of the disease and preventing recurrence. #AML #CancerResearch #Immunotherapy #HealthcareInnovation #CCTx001 #ADV101 Link: DOI:10.1186/s13045-024-01586-x

🌍 Excited to represent Advesya at #ESMO24 next month and have the opportunity to attend presentations and posters, and meet with potential collaborators. We would love to connect, so feel free to reach out! 🤝 🇪🇸 #ESMO2024 #Networking #CCTx001 #ADV101 #Oncology #IL1RAP #CellTherapy #AML #ADC

🚀 We are very pleased to share that our portfolio company Advesya has received approval from the European Medicines Agency (EMA) to initiate the phase 1/2 trial of its lead asset, CCTx-001, to address the medical needs of patients with acute myeloid leukemia (AML).   AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment   The #RESOLVE AML 001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML.   #biopharma #innovation #hematology #oncology #clinicalstudy

🚀 We are delighted to announce that Advesya has received approval from the EMA to start the phase 1/2 trial of our investigational lead asset, CCTx-001, to address the unmet medical needs of patients with relapse and refractory acute myeloid leukemia (AML).   The RESOLVE-AML-001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML. AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment.Advesya is committed to accelerating the development of innovative cancer treatments for patients suffering from this hard-to-treat hematological cancer and who currently have no treatment options. Learn more 👉 www.advesya.com #ClinicalTrials #CellTherapy #Hematology #CancerResearch #AML #InnovativeTherapies #PatientCare #Healthcare #Biotech #CCTx001

Driving innovation through public-private partnerships 🤝 𝗣𝘂𝗯𝗹𝗶𝗰-𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 are pivotal in accelerating research breakthroughs in the field of leukemias (e.g. #AML, #ALL) and related diseases (e.g. #MDS and #MPN). By 𝗰𝗼𝗺𝗯𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗼𝗳 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀, these collaborations 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗮𝘁𝗲 𝘁𝗵𝗲 𝗿𝗮𝗽𝗶𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 of new therapies and diagnostics. 🔬 Such partnerships range 𝗳𝗿𝗼𝗺 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, enabling resource sharing and expertise that are vital for translating discoveries into real-world treatments. They foster a 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁 where diverse perspectives drive innovation and improve patient outcomes. 🚀 Key benefits of public-private partnerships: 👉 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: Merging academic and industry strengths to advance research. 👉 𝗥𝗲𝘀𝗼𝘂𝗿𝗰𝗲 𝗦𝗵𝗮𝗿𝗶𝗻𝗴: Leveraging shared resources to bring innovations to market faster. 👉 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Combining diverse perspectives to drive forward-thinking solutions. At #LEUKEMIA360, we will explore the power of these collaborations in accelerating innovation. Attendees will 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗯𝗲𝘀𝘁 𝗥&𝗗 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀, discover new collaboration opportunities, and contribute to shaping the future of leukemia treatment and diagnosis. By participating, you will have the chance to 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗹𝗲𝘂𝗸𝗲𝗺𝗶𝗮 𝗲𝘅𝗽𝗲𝗿𝘁𝘀, learn about a cutting-edge research and development offer, and explore the transformative potential of partnerships jointly presented by academia and industry. 🌟 Network with pioneers and explore how 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗳𝗳𝗼𝗿𝘁𝘀 𝗰𝗮𝗻 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, allow earlier diagnosis and bring new, more personalized therapies to leukemia patients faster. #Leukemiatherapy #Leukemiadiagnosis #PublicPrivatePartnerships #Innovation #Leukemia360 Le Réseau des Carnot / Advesya / THEMA Saint-Louis Leukemia Institute / AP-HP, Assistance Publique - Hôpitaux de Paris/ Paris Saclay Cancer Cluster (PSCC) / Institut Paoli-Calmettes / Université Paris Cité / OncoSTART Pascal Deschaseaux / Hervé Dombret / Marina Konopleva / Robert Zeiser / Sylvie Freeman / Richard C. A. Sainson / Jian-Qing Mi / Hugues de Thé / Florian Heidel / Virginie Gandemer / Norbert VEY / Jean-Emmanuel Sarry / François Delhommeau / Raphael Itzykson / Stephanie Fugain / Jean-Pierre Bizzari

🎗️ July is Sarcoma and Bone Cancer Awareness Monthn 🎗️🔬 As we raise awareness for sarcoma and bone cancer this month, let’s highlight the crucial role of Advesya's #ADV101 that targets #IL1RAP which is involved in the progression and dissemination of #EwingSarcoma Let's come together to spread awareness, support ongoing research, and advocate for advancements in novel therapies. https://lnkd.in/g_3pTbZW #SarcomaAwareness #BoneCancerAwareness #CancerResearch #ADC

🚀 Exciting developments in potential AML treatment! Sharing this video from #EHA24 where Dr. Nicolas Boissel discusses CCTx-001, a novel approach to tackle AML. CCTx-001 is a first-in-class autologous CAR-T therapy against IL-1RAP that is already showing promising preclinical results . https://lnkd.in/e-mU-zss #EHA24 #CARTCellTherapy #AML #Hematology #CancerResearch #CCTX001 #IL1RAP #Advesya